First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase

CIBA Foundation Symposia

Volumn , Issue 209, 1997, Pages 107-123

  Monia, Brett P ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; ENZYME INHIBITOR; NUCLEOTIDE; RAF PROTEIN;

ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; REVIEW;

ANIMALS; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-RAF; THIONUCLEOTIDES;

EID: 0031299310     PISSN: 03005208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Altmann K-H, Dean N M, Fabbro D et al 1996 Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia 50:168-176
2. Bacon TA, Wickstrom E 1991 Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5′ cap region. Oncogene Res 6:13-19
3. Bennett CF, Chiang H, Shoemaker JE, Mirabelli CK 1992 Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033
4. Bennett CF, Dean N, Ecker DJ, Monia BP 1995 Pharmacological activity of phosphorothioate antisense oligonucleotides: in vivo studies. In: Agrawal S (ed) Methods in molecular medicine: antisense therapeutics. Humana Press, New York, p 13-46
5. Chiang MY, Chen H, Zounes MA, Freier SM, Lima WF, Bennett CF 1991 Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266:18162-18172
6. Crooke ST 1993 Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376
7. Crooke ST 1996 Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev 6:145-147
8. Dean NM, McKay R, Miraglia L 1996 Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C alpha expression. Cancer Res 56:3499-3507
9. De Mesmaeker A, Häner R, Martin P, Moser HE 1995 Antisense oligonucleotides. Acc Chem Res 28:366-374
10. Freier SM, Tinoco I 1975 The binding of complementary oligoribonucleotides to yeast initiator transfer RNA. Biochemistry 14:3310-3314
11. Geiger T, Müller M, Monia BP, Fabbro D 1997 Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res 3:1179-1185
12. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E 1993 Antisense DNA inhibition of tumor growth by c-Ha-rar oncogene in nude mice. Cancer Res 53:577-580
13. Herschlag D, Cech TR 1990 Catalysis of RNA cleavage by the Tetrahymenathermophila ribozyme: kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. Biochemistry 29:10172-10780
14. Kasid U, Pfeifer A, Brennan, T et al 1989 Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243:1354-1356
15. Kasid U, Simeng S, Dent P, Ray S, Whiteside TL, Sturgill TW 1996 Activation of raf by ionizing radiation. Nature 382:813-816
16. Lima W, Monia BP, Freier SM, Ecker DJ 1992 Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31:12055-12061
17. Milligan JF, Matteucci MD, Martin JC 1993 Current concepts in antisense drug design. J Med Chem 36:1923-1926
18. Monia BP, Lesnik E, Gonzalez C et al 1993 Evaluation of 2′-modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514-14522
19. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D 1996a Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat Med 2:668-672
20. Monia BP, Sasmor H, Johnston JF et al 1996b Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human c-raf kinase supports an antisense mechanism of action in tiro. Proc Natl Acad Sci USA 93:15481-15484
21. Monia BP, Johnston JF, Sasmor H, Cummins L 1996e Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem 14533-14540
22. Nesterova M, Cho-Chung Y 1995 A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nat Med 1:528-533
23. Sanghvi YS, Cook PD 1993 Towards second-generation synthetic backbones for antisense oligonucleotides. In: Chu CK, Beker DC (eds) Nucleosides and nucleotides as antitumor and antiviral agents. Plenum Press, New York, p 311-319
24. Schwab G, Chavany C, Duroux I 1994 Antisense oligonucleotides absorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated H-ras-mediated cell proliferation and tumorgenicity in nude mice. Proc Natl Acad Sci USA 91:10460-10464
25. Stein C, Krieg AM 1994 Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 4:67-69
26. Uhlenbeck OC 1972 Complementary oligonucleotide binding to transfer RNA. J Mol Biol 65:25-41
27. Uhlmann E, Peymann A 1990 Antisense oligonucleotides: a new therapeutic principle. Chem Rev 90:543-545
28. Wagner RW 1994 Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335
29. Yazaki T, Ahmed S, Chahlavi A 1996 Treatment of glioblastoma 0-87 by systemic administration of an antisense protein kinase C - a phosphorothioate oligodeoxynucleotide. Mol Pharmacol 50:242-263